Analysis of anti-tumor new drug Dayou with the ®: blocking blood vessel support to "starve" tumor

Pharmaceutical Network, June 22 -anti-tumor drug Dayou tong ® obtained the approval of the State Drug Administration of China (NMPA), the indications of advanced non-scale non-small cell lung cancer and metastatic colorectal cancer.Reporter 19 from the drug's independent research and development of Cinda Biopharmaceutical Group was informed of this newsCinda Bio said it was the second monoclonal antibody drug to be listed after Daberschu ®(Sindilli monoimmune injection).Analysis of the principle mechanism: blocking vascular support to the tumor "starved to death"the introduction, lung cancer is China's incidence, mortality rate is the highest malignanttumor, and colorectal cancer incidence and mortality rate ranked third and fifth, respectively" In layman's terms, the drug blocks blood vessels and eventually 'starves' the tumor in the bodyThe principle mechanism of dayu and ® anti-tumor is to block the vascular endothelial growth factor VEGF, inhibit the vagenesis of the tumor, cut off the blood supply in the tumor area, inhibit the growth and metastasis of the tumor, induce the apoptosis of tumor cells, and thus achieve the therapeutic effect of anti-tumor.The person in charge also said that Dayou and ® can be combined with platinum-based chemotherapy for non-removable late, metastatic or recurrent non-small cell lung cancer patients first-line treatment, can also be combined with fluorone-based chemotherapy for the treatment of patients with metastatic colorectal cancer.Drug Development Hotspots: Immunotherapy and Anti-Angiogenesis TherapyCinda Biomedical Sciences and Strategic Oncology Vice President DrZhou Hui introduced that the combination of immunotherapy and anti-angiogenesis therapy has synergies in the mechanism of action, and is currently a hot spot in the clinical development of anti-tumor drugs .　　Zhou Hui revealed that the results of the ib phase Ib clinical trial for the treatment of advanced liver cell cancer in the ® joint dabo shu ® will be presented at the ASCO annual meeting this year "The data suggest that the combination of these two drugs has achieved initial positive results in patients with advanced hepatocellular carcinoma." He said .　　He also said that Dayou ® is an international quality anti-VEGF monoclonal antibody, has authorized its commercial interestin in the United States and Canada to the United States pharmaceutical company Coherus, which means that Cinda Bio's ability in the field of macromolecular drug research and development is internationally recognized .　　Make it affordable for patients: Two drugs are included in the national health insurance catalog
high-quality biologic drugs that, in the final analysis, are affordable to the population And this is the "first heart" since the establishment of Cinda .　　In November 2019, Daberschu ® became the only PD-1 inhibitor to enter the new national health insurance catalog, costing less than 100,000 yuan a year, one-twelfth of the of similar drugs in the United States Reporters learned that The ® will also be included in the national health insurance directory, so that people can afford to buy .　　Xinda Bio Senior Vice President Yan Hong stressed that Dayou and ® from the project to the listing lasted 8 years, "through a large number of research to establish a scientific and rigorous target." She said that the production of the drug's industrialization base also in line with China's NMPA, the U.S FDA, the European EMA's GMP standards Clinical data show that the drug has good therapeutic effect on advanced non-small cell lung cancer and metastatic colorectal cancer (Complete) .